CagriSema vs Tirzepatide

Will CagriSema beat tirzepatide?

Tirzepatide is approved and prescribed today. CagriSema is an investigational co-formulation awaiting an FDA decision expected in late 2026 — the next major decision on the calendar in this class. Its Phase 3 program reported weight-loss results below what its own Phase 2 data had led the field to expect, which is the most instructive part of the comparison: it is a documented case of a trial-phase signal shrinking when the trial got bigger.

Head-to-head evidence

REDEFINE and SURMOUNT are separate programs run by competing companies with different populations and endpoints. There is no head-to-head trial of CagriSema against tirzepatide, so any ranking between them is inference, not measurement.

A common mistake

Treating a pending FDA decision as an availability date. A decision can be an approval, a rejection or a request for more data, and even an approval is followed by launch timing, supply build-out and coverage decisions.

Educational use only, never medical advice. No doses.